Reducing the Risk of Stroke in Elderly Patients with Hypertension: a Critical Review of the Efficacy of Antihypertensive Drugs

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2005 Jun 25

PMID 15974641

Citations 5

Authors

Peter M Nilsson

Affiliations

Soon will be listed here.

Abstract

The risk of ischaemic or haemorrhagic stroke is increased in patients with hypertension, with a linear relationship between elevation of blood pressure and stroke risk being seen even in normotensive individuals. In elderly subjects it has been shown that systolic blood pressure (SBP) elevation in particular is the most important risk predictor for stroke. This is also the rationale for treating elevated SBP in the elderly. Several clinical trials have repeatedly shown the benefits of blood pressure control for prevention of stroke and also for dementia, both of the multi-infarct and Alzheimer subtype. Remaining research questions involve the proper and evidence-based choice of drug treatment in the elderly hypertensive patient. In spite of the introduction of many newer antihypertensive drugs, use of thiazide diuretics is still one of the best treatment choices, as this class of drugs is well proven and cost effective. Another question concerns when and how to treat patients >80 years of age. An ongoing randomised clinical trial, the Hypertension in the Very Elderly trial, is currently trying to evaluate risks and benefits of antihypertensive treatment in this age category.

Citing Articles

Secondary prevention of stroke in the elderly: focus on drug therapy.

Arnan M, Burke G, Bushnell C Drugs Aging. 2014; 31(10):721-30.

PMID: 25212952 DOI: 10.1007/s40266-014-0212-2.

Characterizing the elastic properties of tissues.

Akhtar R, Sherratt M, Cruickshank J, Derby B Mater Today (Kidlington). 2012; 14(3):96-105.

PMID: 22723736 PMC: 3378034. DOI: 10.1016/S1369-7021(11)70059-1.

Tissue elasticity and the ageing elastic fibre.

Sherratt M Age (Dordr). 2009; 31(4):305-25.

PMID: 19588272 PMC: 2813052. DOI: 10.1007/s11357-009-9103-6.

Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.

Bushnell C, Colon-Emeric C Drugs Aging. 2009; 26(3):209-30.

PMID: 19358617 PMC: 3740382. DOI: 10.2165/00002512-200926030-00003.

Drug therapy for the secondary prevention of stroke in hypertensive patients: current issues and options.

Luders S Drugs. 2007; 67(7):955-63.

PMID: 17488141 DOI: 10.2165/00003495-200767070-00001.

References

Forette F, Seux M, Staessen J, Thijs L, Babarskiene M, Babeanu S . The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162(18):2046-52. DOI: 10.1001/archinte.162.18.2046. View

Launer L, Ross G, Petrovitch H, Masaki K, Foley D, White L . Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000; 21(1):49-55. DOI: 10.1016/s0197-4580(00)00096-8. View

Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson L, Nilsson L . 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347(9009):1141-5. DOI: 10.1016/s0140-6736(96)90608-x. View

. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24):3255-64. View

Messerli F, Grossman E, Goldbourt U . Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998; 279(23):1903-7. DOI: 10.1001/jama.279.23.1903. View

Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View

Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B . The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21(5):875-86. DOI: 10.1097/00004872-200305000-00011. View

Bulpitt C, Beckett N, Cooke J, Dumitrascu D, Gil-Extremera B, Nachev C . Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003; 21(12):2409-17. DOI: 10.1097/00004872-200312000-00030. View

. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21(6):1011-53. DOI: 10.1097/00004872-200306000-00001. View

10.

Safar M, Benetos A . Factors influencing arterial stiffness in systolic hypertension in the elderly: role of sodium and the renin-angiotensin system. Am J Hypertens. 2003; 16(3):249-58. DOI: 10.1016/s0895-7061(02)03259-4. View

11.

PERRY Jr H, Davis B, Price T, Applegate W, Fields W, Guralnik J . Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000; 284(4):465-71. DOI: 10.1001/jama.284.4.465. View

12.

Nilsson P, Gudbjornsdottir S, Eliasson B, Cederholm J . Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. J Hum Hypertens. 2003; 17(1):37-44. DOI: 10.1038/sj.jhh.1001503. View

13.

Tuomilehto J, Rastenyte D, Birkenhager W, Thijs L, Antikainen R, Bulpitt C . Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999; 340(9):677-84. DOI: 10.1056/NEJM199903043400902. View

14.

. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

15.

Khalili P, Nilsson P, Nilsson J, Berglund G . Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a population-based prospective study of middle-aged men. J Hypertens. 2002; 20(9):1759-64. DOI: 10.1097/00004872-200209000-00019. View

16.

Fournier A, Messerli F, Achard J, Fernandez L . Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004; 43(8):1343-7. DOI: 10.1016/j.jacc.2003.10.060. View

17.

Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A . Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology. 1999; 53(9):1948-52. DOI: 10.1212/wnl.53.9.1948. View

18.

Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile A, Wolfe C . Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke. 2003; 34(5):1114-9. DOI: 10.1161/01.STR.0000068410.07397.D7. View

19.

Carlberg B, Samuelsson O, Lindholm L . Atenolol in hypertension: is it a wise choice?. Lancet. 2004; 364(9446):1684-9. DOI: 10.1016/S0140-6736(04)17355-8. View

20.

Kjeldsen S, Dahlof B, Devereux R, Julius S, Aurup P, Edelman J . Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002; 288(12):1491-8. DOI: 10.1001/jama.288.12.1491. View